Thoughts on this? >> GSK says Dovato was as effective as Biktarvy in head-to-head HIV trial — but patients gained less weight >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharmaceutical #pharma #biotech
LucidQuest’s Post
More Relevant Posts
-
Thoughts on this? >> Gilead, Merck's experimental long-acting HIV treatment heads to Phase 3 >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharma #biotech #productmarketing #pharmaceutical
Gilead, Merck's experimental long-acting HIV treatment heads to Phase 3
endpts.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Gilead, Merck's experimental long-acting HIV treatment heads to Phase 3 >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #pharmaceutical #pharma #biotech #productmarketing
Gilead, Merck's experimental long-acting HIV treatment heads to Phase 3
endpts.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> GSK’s ViiV stops development of Phase 2 HIV antiviral >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #healthcare #pharmaceutical #productmarketing
GSK’s ViiV stops development of Phase 2 HIV antiviral
endpts.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> BridgeBio's $250M offering; ViiV's PhI data for ultra-long-acting HIV treatment >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #biotech #healthcare
BridgeBio's $250M offering; ViiV's PhI data for ultra-long-acting HIV treatment
https://endpts.com
-
Thoughts on this? >> In rare move, Colombia issues compulsory license for HIV medicine in effort to expand access >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #healthcare #biotech #productmarketing
In rare move, Colombia issues compulsory license for HIV medicine in effort to expand access
https://endpts.com
-
ViiV's long-acting Cabenuva beats out daily oral HIV treatments in PhIII >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharmaceutical #pharma #healthcare
ViiV's long-acting Cabenuva beats out daily oral HIV treatments in PhIII
https://endpts.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
ViiV's long-acting Cabenuva beats out daily oral HIV treatments in PhIII >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharmaceutical #pharma #biotech
ViiV's long-acting Cabenuva beats out daily oral HIV treatments in PhIII
https://endpts.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> In rare move, Colombia issues compulsory license for HIV medicine in effort to expand access >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #healthcare #biotech #pharma #productmarketing
In rare move, Colombia issues compulsory license for HIV medicine in effort to expand access
https://endpts.com
-
Thoughts on this? >> TheBodyPro: For the HIV/AIDS Workforce >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #healthcare #pharmaceutical
TheBodyPro: For the HIV/AIDS Workforce
thebodypro.com
-
Good news: a big drug company voluntarily licensed its ground-breaking shot to block HIV infections, for free, to generics makers in the global south, so it will be available at low cost in 120 countries. Less good news: a swath of middle income countries are left out of the deal, including countries that make up 20% of new HIV infections – the drug maker will sell its patented product in those countries. What will it cost, and will vulnerable people be able to afford it? They're not saying. Even darker news: those excluded countries include Brazil, Peru and Mexico, where the clinical trials to test the drug were conducted. https://lnkd.in/gzrvYwuA
Gilead Agrees to Allow Generic Version of Groundbreaking H.I.V. Shot in Poor Countries
https://www.nytimes.com
